Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer

Abstract

In marked contrast to the results seen in patients with BRAF V600E-mutant melanoma, single-agent vemurafenib did not show meaningful clinical activity in patients with BRAF V600E mutant CRC. Combination strategies are now under development and may be informed by the presence of intratumor heterogeneity of KRAS and NRAS mutations.